Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $173 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.
GILD is expected to release its Q1 2026 earnings soon. Ahead of the event, analysts expect the company’s EPS to be $1.86 on a diluted basis, up 2.8% from $1.81 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in three of its last four quarters, while missing the mark once.
For fiscal 2026, analysts project the company’s EPS to be $8.66, up 6.3% from $8.15 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 11.2% year over year (YoY) to $9.63 in fiscal 2027.
GILD stock has grown 26.1% over the past 52 weeks, outperforming the S&P 500 Index’s ($SPX) 16.4% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 2.9% rise during the same time frame.
On Feb. 11, GILD stock rose 5.8% following the release of its Q4 2025 earnings. The company’s revenue amounted to $$7.9 billion and exceeded Wall Street forecasts. Moreover, its adjusted EPS for the quarter came in at $1.86, also coming in on top of the Street’s estimates. Gilead expects full-year earnings in the range of $8.45 to $8.85 per share.
Analysts are highly bullish on GILD, with the stock having a “Strong Buy” rating overall. Among the 32 analysts covering the stock, 22 are recommending a “Strong Buy,” two recommend a “Moderate Buy,” and eight suggest a “Hold.” GILD’s average analyst price target is $158.86, indicating an upside of 14.2% from the current levels.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
